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Abstract
In 2008, the interest in metabolic and endocrine issues and their
consequences in critically ill patients was high. A large proportion
of the research papers related to these issues was related to the
metabolism of glucose and its control and to the changes in body
composition, including muscular weakness. In Critical Care,
original reports from investigations of glucose physiology and
clinical data from observational and interventional studies were
published. Important reports of the effects of hormone analogues,
such as vasopressin and hydrocortisone, and early antioxidants in
selected subpopulations were also available in 2008.
In 2008, interest in endocrine and metabolic disturbances
occurring during critical illness was still growing. New clinical
and experimental data have been published and some of
these provide exciting links between pathophysiological
changes to functional outcome variables. This review intends
to summarise the new data published in these areas in 2008
in Critical Care and elsewhere. The fields covered will include
‘Glucose metabolism and control’, ‘Body composition and
muscular weakness’ and ‘Other interventions’.
Glucose metabolism and control
The physiology of glucose and the effects of glucose control
represented major fields of investigation, fuelled by the
discrepancy between the results of the pioneering ‘Leuven I’
study [1] and later reports. In 2008, three major prospective
trials of glucose control were published by teams from
Colombia [2], Germany [3] and Saudi Arabia [4]. All of these
trials were consistently unable to reproduce the benefits
reported from the Leuven I study; that is, survival was not
increased in patients randomly assigned to tight glucose
control by intensive insulin therapy. The discordances between
these data and those from the Leuven I study [1] underlie the
numerous unanswered issues and the need for pre-clinical and
clinical investigations in the field. In Critical Care in 2008, we
had the privilege of publishing one of the prospective trials [2]
and other papers related to the issues of glucose physiology
and control in the critically ill, which can be pooled into
physiological insights and reports of clinical data.
Physiological insights
As reported in Critical Care, in a very detailed investigation of
a set of 37 patients scheduled for cardiac surgery, Lehrke
and colleagues [5] sought to better understand the
determinants of insulin resistance, the major mechanism of
stress hyperglycaemia [6,7]. These investigators hypothesised
that both inflammatory mediators (the cytokines interleukin-6
[IL-6] and tumour necrosis factor) and hormones (cortisol,
resistin, leptin and adiponectin) independently increased the
insulin resistance. This hypothesis is appealing as it is based
on robust recent evidence [8] from data recorded in obese
patients and in inflammatory situations. The resistance to
insulin was assessed by both the insulin requirements to
maintain ‘euglycaemia’ and an insulin glycaemic index
deduced from the result of the multiplication of blood glucose
by the circulating insulin concentration (the sum of
exogenous and endogenous insulin). Using a likelihood ratio
test, these authors could elegantly show that cortisol was the
best predictor of insulin resistance, followed by IL-6, leptin
and adiponectin. Daily clinical practice could be influenced in
the future as these data can serve to identify additional risk
factors for the development of insulin resistance, namely
before surgery is scheduled [9].
Another interesting physiological approach was published
last year by Otto and colleagues [10]. These investigators
sought to discriminate the effects of insulin from those of
hyperglycaemia in a cell culture system of human poly-
morphonuclear cells stimulated with a low dose of lipopoly-
saccharide. The outcome variable recorded included the
release of IL-1 and IL-6, the phagocytosis activity, the
oxidative burst and a flow cytometric analysis. The most
salient finding was the induction of IL-6 release after
incubation of cells, already with 250 mg/dL of glucose, a
concentration that can be found in clinical situations. The
release of IL-1 needed higher glucose concentrations and the
hyperglycaemia-induced production of both cytokines was
partially inhibited by insulin. Both the oxidative burst and the
phagocytic activity were decreased by hyperglycaemia and
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by hyperosmolarity. From a clinical standpoint, these data can
be viewed as a partial explanation of the susceptibility of
hyperglycaemic patients or poorly controlled diabetics to
infections and ischaemia.
Clinical data
Data reported from clinical investigations in Critical Care last
year can be regarded as either ‘observational’ or ‘inter-
ventional’. In the first category, two different teams
investigated particular aspects of glucose metabolism during
moderately strict glucose control (target blood glucose of 4.4
to 8.0 mmol/L) in selected populations of critically ill patients.
The first study was performed in 31 patients with sub-
arachnoid haemorrhage [11]. In these patients, several
indices of brain metabolism and damage (glucose, lactate,
pyruvate, glycerol and glutamate) were continuously
measured by microdialysis, and correlations with the blood
glucose levels were followed. Basically, the authors found
that the glucose concentration measured in the cerebral
tissue was much lower than the plasma concentration. In
spite of the low brain glucose levels, there was no evidence
of brain energy failure, as the lactate and pyruvate
concentrations remained unchanged. However, the glycerol
level tended to increase, consistent with cell membrane
damage. These important findings in a selected group of
patients are consistent with earlier work from Vespa and
colleagues [12], who performed a similar study in a broader
population of brain-injured patients. The data presented by
Schlenk and colleagues [11] are consistent with the recent
report of Oddo and colleagues [13], who reported a risk of
brain energy deficit (defined by an elevated lactate-to-
pyruvate ratio) in a population of 20 brain-injured patients
when blood glucose fell to below 6.7 mmol/L. The data
presented by Schlenk and colleagues [11] will definitely
contribute to the development of recommendations for blood
glucose targets in the specific population of ‘neurocritical
care patients’ in whom both hyperglycaemia and
hypoglycaemia, even moderate, can induce detrimental
effects, as recently reviewed by Bilotta and colleagues [14].
In another setting, but using the same intermediate glucose
target, Waeschle and colleagues [15] compared the severity
of sepsis with the time course of glycaemia, including the
incidence of hyperglycaemia and hypoglycaemia and glucose
variability, in a population of 191 patients. This thorough
analysis was clearly needed to confirm the long-held belief
that the incidences of both hyperglycaemia and hypo-
glycaemia, and hence glucose variability, increased as a
function of the severity of sepsis. Interestingly, the multivariate
analysis indicated that the frequency of hypoglycaemia and
the amplitude of glucose variability were correlated and
represented predictors of poor prognosis. These important
findings corroborate other data recorded in septic patients
(that is, the association between high glucose variability and
poor outcome in septic patients) [16]. The correlation
between hypoglycaemia and higher mortality was reported in
each of the prospective trials on glucose control [17] and
was found as an independent predictor of mortality in a large
cohort of critically ill patients [18]. However, this correlation
may not imply a direct toxicity of insulin treatment, as recently
suggested in patients after myocardial infarction [19].
Two important interventional studies and a detailed analysis
of the indices of the quality of glucose control were also
published last year in Critical Care. The first interventional
study [2], performed in Colombia as a single-centre trial in a
mixed (medico-surgical) intensive care unit (ICU), was
designed to confirm the external validity of the Leuven I study
[1]. Twenty-eight-day mortality was the primary outcome
variable, and 504 patients were enrolled and randomly assigned
to intensive insulin therapy (target of 4.4 to 6.1 mmol/L)
versus a ‘standard’ target of 10.0 to 11.1 mmol/L. Even
though there was an overlap between blood glucose
achieved in both groups, no advantage in favour of intensive
insulin therapy was found. This study, like several other
prospective randomised controlled trials [3,4,20,21],
including one study in very-low-birth-weight infants [22], was
unable to confirm the survival benefit afforded by tight
glucose control by intensive insulin therapy reported in the
pioneering study [1]. The results of two recent meta-analyses
[23,24] indeed show no survival benefit but a fivefold
increase in the rate of hypoglycaemia in the patients randomly
assigned to intensive insulin therapy. However, these trials
should not discourage the intensive care community from
searching for improvements in glucose control, possibly using
different glucose targets [25]. In this regard, the data
provided by Chase and colleagues [26] are of major
importance. Using a combined strategy of adaptation of
insulin infusion and feeding rates in a cohort of 371 patients,
these investigators reported remarkable results in terms of
percentage of blood glucose values within the desired range.
This represents a major improvement as compared with the
previous performance of this centre, assessed in a
retrospective cohort of 413 matched patients. Very impor-
tantly, this improvement in glucose control was associated
with decreased hospital mortality in patients who stayed in the
ICU for more than 3 days. These very impressive data suggest
that the degree of achievement of a pre-defined glucose target
is the key factor of any strategy used to control glycaemia. In
fact, there are several indicators of the success and ‘quality’ of
glucose control. The long list of published quality indicators
was systematically reviewed by Eslami and colleagues [27].
As stated by the authors, there is a clear need for an
unambiguous indicator reference subset rather than a jungle
of potential indicators. This important article will probably be
very helpful for many investigators in the field of glucose
control when designing interventional studies and selecting
end points and indices of quality of any intervention.
Body composition and muscular weakness
Long-term critically ill patients are at very high risk of
developing severe malnutrition, even when nutrition support isadapted using the usual monitoring tools. The consequences
of this severe malnutrition on body composition are mostly
unknown. Last year in Critical Care, Reid and colleagues [28]
reported a carefully monitored 12-month course of body
composition and functional capacity recorded in a young
woman recovering from an episode of extrapontine
myelinolysis. In spite of an intensive rehabilitation program,
muscle wasting and functional compromise were still very
impressive after 1 year. This report is needed to promote and
foster further research to improve the physical and nutritional
management of chronically critically ill patients!
Indeed, the aspects of muscular rehabilitation following long-
term critical illness are frequently overlooked. A compre-
hensive report by a multidisciplinary task force of the
European Respiratory Society and the European Society of
Intensive Care Medicine [29] underlined the need to
standardise the practice of physiotherapy and to increase the
awareness of the benefits of prevention and treatment of
immobility and muscular de-conditioning. In fact, the
understanding and knowledge of the pathophysiology and
management of critical illness polyneuropathy and myopathy
are progressively increasing. A comprehensive and thorough
review of this topic was published in Critical Care in 2008
[30]. Among novel and efficient interventions, the early
mobility systematic protocol performed by a specialised team
is efficient [31] and was found to be particularly cost-effective
in patients with acute respiratory failures admitted to a
medical ICU as it reduced the lengths of stay in the ICU and
in the hospital without increasing the costs [32].
Other interventions
In 2008, several large trials designed to test the hypotheses
of improved outcomes following administration of analogues
of hormones, presumably deficient during septic shock (that
is, vasopressin and hydrocortisone), were conducted. In the
first study, the Vasopressin and Septic Shock Trial (VSST)
[33], 778 patients underwent random assignment to receive
noradrenaline or vasopressin titrated and tapered to maintain
a target blood pressure. There was no difference in the
primary end point (28-day mortality) or in any of the rates of
adverse events. Similarly, in the Corticosteroid Therapy of
Septic Shock (CORTICUS) trial [34], 499 patients were
randomly assigned to hydrocortisone or to placebo during the
early phase of septic shock. Even though the reversal of
shock was hastened in the patients treated with
hydrocortisone, there was no difference in survival but an
increased incidence of secondary septic shock. Finally,
based on a high probability of elevated oxidative stress [35],
three groups of critically ill patients (postoperative cardiac or
respiratory failure after cardiac surgery, major trauma or
severe subarachnoid haemorrhage) were randomly assigned
to a combination of antioxidants (trace elements and vitamins)
or placebo [36]. The primary outcome variable of the study
was a change in the acute kidney injury score, and 200
patients were enrolled. Although the antioxidant therapy was
able to restore circulating values of its different components
within the normal range, only the inflammatory response
(estimated by the C-reactive protein level) in the trauma and
in the subarachnoid haemorrhage groups was improved.
Large studies using different doses of different combinations
of antioxidants administered in different populations at
different times will definitely be needed to accurately define
the place of antioxidants in the treatment of critically ill
patients [35]. The ‘negative’ results of these three large trials
are very important as they stress the complexity of manipu-
lating the hormonal and oxidative pathways during critical
illness and the need for further pre-clinical research.
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